Evidence map›Paper›PMID 36652178›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2023

Albumin-Bilirubin Grade and Tumor Burden Score Predict Outcomes Among Patients with Intrahepatic Cholangiocarcinoma After Hepatic Resection: a Multi-Institutional Analysis.

Muhammad Musaab Munir, Yutaka Endo, Henrique A Lima, Laura Alaimo, Zorays Moazzam, Chanza Shaikh, George A Poultsides, Alfredo Guglielmi, Luca Aldrighetti, Matthew Weiss and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 16 institutions in 10 countries.

Muhammad Musaab MunirDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Yutaka EndoDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Henrique A LimaDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Laura AlaimoDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Zorays MoazzamDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Chanza ShaikhDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
George A PoultsidesDepartment of Surgery, Stanford University, Stanford, CA, USA.
Alfredo GuglielmiDepartment of Surgery, University of Verona, Verona, Italy.
Luca AldrighettiDepartment of Surgery, Ospedale San Raffaele, Milan, Italy.
Matthew WeissDepartment of Surgery, John Hopkins Hospital, Baltimore, MA, USA.
Todd W BauerDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.
Sorin AlexandrescuDepartment of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
Minoru KitagoDepartment of Surgery, Keio University, Tokyo, Japan.
Shishir K MaithelDepartment of Surgery, Emory University, Atlanta, GA, USA.
Hugo P MarquesDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Guillaume MartelDepartment of Surgery, University of Ottawa, Ottawa, ON, Canada.
Carlo PulitanoDepartment of Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
Feng ShenDepartment of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
François CauchyDepartment of Hepatibiliopancreatic Surgery, APHP, Beaujon Hospital, Clichy, France.
Bas Groot KoerkampDepartment of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City, University School of Medicine, Yokohama, Japan.
Timothy M PawlikDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Tim.Pawlik@osumc.edu.ORCID 0000-0002-7994-9870
The Ohio State University Wexner Medical Center · USEmory University · USErasmus University Rotterdam · NLHôpital Beaujon · FRHospital Curry Cabral · PTInstitutul Clinic Fundeni · ROIRCCS Ospedale San Raffaele · ITJohns Hopkins Hospital · USKeio University · JPSecond Military Medical University · CNStanford University · USThe University of Sydney · AUUniversity of Ottawa · CAUniversity of Verona · ITUniversity of Virginia · USYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic role of tumor burden score (TBS) relative to albumin-bilirubin (ALBI) grade among patients undergoing curative-intent resection of ICC has not been examined.

methodsWe identified patients who underwent curative-intent resection for ICC between 1990 and 2017 from a multi-institutional database. Multivariable analysis was performed to assess the effect of TBS relative to ALBI grade on both short- and long-term outcomes.

resultsAmong 724 patients, 360 (49.7%) patients had low TBS and low ALBI grade, 142 (19.6%) patients had low TBS and high ALBI grade, 138 (19.1%) patients had high TBS and low ALBI grade, and 84 patients (11.6%) had high TBS and high ALBI grade. Decreased tumor burden was associated with better long-term outcomes among patients with both low (5-year OS; low TBS vs. high TBS: 52.4% vs 21.4%; p < 0.001) and high ALBI grade (5-year OS; low TBS vs. high TBS: 40.7% vs 12.0%; p < 0.001). On multivariable analysis, higher ALBI grade was associated with greater odds of an extended hospital LOS (> 10 days) (OR 2.80, 95%CI 1.62-4.82; p < 0.001), perioperative transfusion (OR 2.04, 95%CI 1.25-3.36; p = 0.005), 90-day mortality (OR 2.56, 95%CI 1.12-5.81; p = 0.025), as well as a major complication (OR 1.99, 95%CI 1.13-3.49; p = 0.016) among patients with similar tumor burden. Of note, patients with high TBS and high ALBI grade had markedly worse overall survival compared with patients who had low TBS and low ALBI grade disease (HR 2.27; 95%CI 1.44-3.59; p < 0.001). Importantly, high TBS and high ALBI grade were strongly associated with both early recurrence (88.1%%) and 5-year risk of death (96.4%).

conclusionBoth TBS (i.e., tumor morphology) and ALBI grade (i.e., hepatic function reserve) were strong predictors of outcomes among patients undergoing ICC resection. There was an interplay between TBS and ALBI grade relative to patient prognosis after hepatic resection of ICC with high ALBI grade predicting worse outcomes among ICC patients with different TBS.

Indexed as

Bile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsBile Ducts, IntrahepaticBilirubinHumansPrognosisRetrospective StudiesSerum AlbuminTumor BurdenBilirubinSerum AlbuminAlbumin-bilirubin gradeIntrahepatic cholangiocarcinomaOverall survivalTumor burden

Identifiers

PMID36652178
OpenAlexW4317215146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.